ANCA defines the clinical disease manifestations of vasculitis

Sarcoidosis Vasculitis and Diffuse Lung Disease

Volumn 13, Issue 3, 1996, Pages 221-226

  Zhao, Ming Hui ^a   Lockwood, C Martin ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

ANCA; Clinical manifestations; Vasculitis

Indexed keywords

AUTOANTIBODY; AZUROCIDIN; DEFENSIN; GRANULOCYTE ANTIBODY;

CLINICAL FEATURE; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; PRIORITY JOURNAL; SHORT SURVEY; VASCULITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODY SPECIFICITY; ANTIGENS, CD; ANTIMICROBIAL CATIONIC PEPTIDES; AUTOANTIGENS; BLOOD PROTEINS; CARRIER PROTEINS; DEFENSINS; HUMANS; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MEMBRANE GLYCOPROTEINS; MYELOBLASTIN; PEROXIDASE; SERINE ENDOPEPTIDASES; VASCULITIS;

EID: 0029742469     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (59)

1. Gross WI, Csernok E, Helmehen U: Antineutrophil cytoplasmic autoantibodics, autoantigens, and systemic vasculitis. APMIS 1995; 103: 81-97.
2. Hagen EC: Development and standardization of solid-phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA) for clinical application: report of a large clinical evaluation study. Clin Exp Immunol 1995; 101: 29.
3. Goldschmeding R, Cohen-Tervaert JW, van der School CE, van der Veen C, Kallenberg CGM, von dem Borne AEGKr: ANCA, anti-myeoloperoxidase, and anti-elastase: three members of a novel class of autoantibodies against myeloid lysosomal enzymes. APMIS 1989; 97 (S6): 48-19.
4. Nassberger L, Jonsson H, Sjoholm AG, Sturfelt G, Heubner A: Circulating antielastase in systemic lupus erythematosus. Lancet 1989; I: 509.
5. Halbwachs-Mecarelli L, Nusbaum P, Noel LII et al: Antineutrophil cytoplasmic antibobies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis; Clin Exp Immunol 1992; 90: 79-84.
6. Coremans IEM, Hagen EC, Daha MR et al: Antilactoferrin antibodies in patients with arthritis are associated with vasculitis. Arthritis Rheum 1992; 35: 1466-1475.
7. Schmitt WII; Csernok E, Flesch BK, Hauschild S, Gross WL: Autoantibodies directed against lysozyme: a new target antigen for anti-neutrophil cytoplasmic antibodies (ANCA). Adv Exp Med Biol 1993; 336: 267-272.
8. Kancko K, Suzuki Y, Yamashiro Y, Yabuta S: Is p-ANCA in ulcerative colitis directed against glucuronidase? Lancet 1993; 341: 320.
9. Moodie FDL, Leaker B, Cambridge G, Totty NF, Segal AW: Alpha-enolase: a novel cytosolic autoantigen in ANCA positive vasculitis. Kidney Int 1993; 43: 675-681.
10. Short AK, Lockwood CM: Antigen-specificity in hydralazine associated ANCA positive systemic vasculitis. Q J Med 1995; 88 (11): 775-785.
11. Zhao MH, Jones SJ, Lockwood CM: Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis: Clin Exp Immunol 1995; 99: 49-56.
12. Kain R, Matsui K, Exner M et al: A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: The lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells. J Exp Med 1995; 181: 585-597.
13. Gallin MY, Jacobi AB, Buttner DW, Schonberger O, Marti T, Eritmann KD: Human autoantibody to defensin-Disease association with hyperreactive onchoceriasis (SOWDA). J Exp Med 1995; 182: 41-47.
14. Zhao MH, Locjwood CM: Azurocidin is a novel antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in systemic vasculitis. Clin Exp Immunol 1996. In press.
15. Halbwachs-Mecarelli L, Nusbaum P, Lesavre P, Witko-Sarsat V, Bessou G, Noel III, Gabay J: Anti-azurocidin p-ANCA in a patient with Wegener's syndrome. Clin Exp Immunol 1995; 101 (S1): 50 (abstract).
16. Falk RJ, Becker M, Terrell R, Jennette JC: Antigen specificity of p-ANCA and c-ANCA. The Third International Workshop on ANCA. Am J Kidney Dis 1991; 18: 197 (abstract 6).
17. Zhao MH, Jayne DRW, Ardiles L, Culley F, Hodson ME, Lockwood CM: Autoantibodies against bactericidal/permeability-increasing protein (BPI) in cystic fibrosis. Q J Med 1996. In press.
18. Hamilton M, Zhao MH, Chapman P et al: Bactericidal/permeability-increasing protein (MPI)- A novel target for p-ANCA in inflammatory bowel disease. Gastroenterology 1995; 108 (4 SS): 830 (abstract).
19. Herzberg C, Csernok E, Stoffet M, Carroll SF, Szymkowiak C, Gross WL: Disease associations of ANCA with specificity for bactericidal/permeability-increasing protein (BPI). Clin Exp Immunol 1995; 101 (S1): 41 (abstract).
20. Kallenberg CGM, Brouwer F, Weening JJ, Cohen Tervaert JW: Anti-neutrophil cytoplasmic antibodies: Current diagnostic and pathophysiological potential. Kidney International 1994; 46: 1-15.
21. Weersink AJ, van Kessel KP, van der Tol ME at al: Human granulocytes express a 55 kD lipopolysaccharide-binding protein on the cell surface that is identical to the bactericidal/permeability-increasing protein. J Immunol 1993; 150: 4532-1540.
22. Elsbach P and Weiss J: The bactericidal/permeability-increasing protein (BPI), a potent element in host defense against Gram-negative bacteria and lipopolysaccharide. Immunology 1993; 187: 417-429.
23. Vandermeer TJ, Menconi MJ, O'Sullivan BP et al: Bactericidal/permeability-increasing protein ameliorates acute lung injury in porcine endotoxaemia. Journal of Applied Physiology 1994; 76(5): 2006-2014.
24. Arditi M, Zhou J, Huang SH, Luchett PM, Marra MN, Kim KS: Bactericidal/permeability-incrcasing protein protects vascular endothelial cells from lipopolysaccharide-induced activation and injury. Infect Immun 1994; 62 (9): 3930-3936.
25. 2-independent bactericidal system. I Clin Invest 1982; 69: 959-970.
26. Gray PW, Flaggs G, Leong SR et al: Cloning of the cDNA of a human neutrophiol bactericidal protein. Structural and functional correlations. J Biol Chem 1989; 264: 9505-9509.
27. Jones SJ, Zhao MH, Elliott JD, Lockwood CM: The antigenicity of bactericidal/permeability-increasing protein (BPI) is threatened by serine proteinases. Clin Exp Immunol 1995; (S1): 36(absrtact).
28. Pereira HA, Spitznagel JK, Pohl J at al: CAP37, a 37 kD human neutrophil granule cationic protein shares homology with inflammatory proteinases. Life Sci 1990; 46: 189.
29. Gabay JE, Scott RW, Campanelli D et al: Antibiotic proteins of human polymorphonuclear leucocytes. Proc Natl Acad Sci USA 1989; 86: 5610-5614.
30. Campanelli D, Detmers PA, Nathan CF, Gabay JE: Azurocidin and a homologous serine protease from neutrophils. Differential antimicrobial and proteolytic properties. J Clin Invest 1990; 85: 904-915.
31. Miyasaki KT, Bodeau AL: Human neutrophil azurocidin synergizes with leukocyte elastase and cathepsin G in the killing of Capnocytophaga sputigena. Infect Immun 1992; 60: 4973-1975.
32. Spitznagel J: Antibiotic proteins of human neutrophils. J Clin Invest 1990; 86: 1381-1386.
33. Ostergaard E, Flodgaard H: A neutrophil-derived proteolytic inactive elastase homologue (hHBP) mediates reversible contraction of fibroblastis and endothelial cell monolayers and stimulates monocyte survival and thrombospondin secretion. J Leukoc Biol 1992; 51: 316-323.
34. Hill CP, Yee J, Selsted ME, Eisenberg D: Crystal structure of defensin HNP-3, an amphiphilic dimer: mechanisms of membrane permeabilization. Science 1991; 251: 1481-1485.
35. Gabay JE and Almeida RP: Antibiotic peptides and serine current homologs in human polymorphonuclear leucocytes: defensins and azurocidin. Current Opinion in Immunology 1993; 5: 97-102.
36. Rakita RM, Michel BR, Rosen H: Inactivation of Escherichia-Coli penicillin-binding proteins by human neutrophils. Infect Immun 1994; 62: 162-165.
37. Good MF: What can a worm teach us about autoimmunity? Lancet 1995; 346: 1311-1312 (Letter).
38. Davies DJ, Moran JE, Niall JF, Ryan GB: Segmental necrotizing glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Brit Med J 1982; 258: 606-609.
39. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, De Jong PE, Kallenberg CGM: Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener's granulomatosis. Ann Intern Med 1994; 120: 12-17.
40. Goeken JA: Antineutrophil cytoplasmic antibodies: a useful serological marker for vasculitis. J Clin Immunol 1991; 11: 161-174.
41. Stegeman CA, Cohen Tervaert JW, De Jong PE, Kallenberg CGM: Prevention of relapses of Wegener's granulomatosis by treatment with trimethoprim-sulfamethoxazole. A multicenter placebo controlled trial in 81 patients. Clin Exp Immunol 1995; 101 (S1): 37 (abstract 37).
42. Bartunkova J, Fucikova T, Tesar V, Janatkova I, Rychlik, I Sulkova S: Antineutrophil cytoplasmic antibody-positive sera inhibit candidacidal activity of granulocytes. Exp Nephrol 1995; 3: 58-60.
43. Jennette JC, Falk RJ: Pathogenic potential of anti-neutrophil cytoplasmic autoantibodies [editorial; comment]. Lab Invest 1994; 70 (2): 135-137.
44. Csernok E, Ernst M, Schmitt W, Bainton DF, Gross WL: Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 1994; 95 (2): 244-250.
45. Mayet WJ, Meyer-zum Buschenfelde KH: Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells. Clin Exp Immunol 1993; 94 (3): 440-446.
46. Keogan MT; Rifkin I, Ronda N, Lockwood CM, Brown DL: Anti-neutrophil cytoplasmic antibodies (ANCA) increase neutrophil adhesion to cultured human endothelium. Adv Exp Med Biol 1993; 336: 115-119.
47. Falk RJ, Terrell RS, Charles LA, Jennette JC: Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990; 87: 4115-4119.
48. Kekow J, Szymkowiak CH, Sticherling M, Schroder JM, Christophers E, Gross WL: Pro-and anti-inflammatory cytokines in primary systemic vasculitis. In: Gross WL (Ed): ANCA-associated vasculitides. Plenum Press, New York and London: 1993, pp. 341-344.
49. Roux-Lombard P, Lin JM, Peter JB, Dayer JM: Elevated serum levels of TNF soluble receptors in patients with positive anti-neutrophil cytoplasmic antibodies. Br J Rheumatol 1994; 33: 428-431.
50. Mulder AHL, Heeinga P, Brouwer E, Limburg PC, Kallenberg CGM; Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a FcγRll-dependent process. Clin Exp Immunol 1994; 98: 270-278.
51. Forges AJ, Redecha PB, Kimberly WT, Csernok E, Gross WL, Kimberly RP: Activation of neutrophil cytoplasmic antibodies engage and activate human neutrophils via FcγRlla. J Immunol 1994; 153: 1271-1280.
52. Mayet WJ, Csernok E, Szymkowiak C, Gross WL, Meyer-zum Buschenfelde KH: Human endothelial cells express proteinase 3, the target antigen of anticytoplasmic antibodies in Wegener's granulomatosis. Blood 1993; 82 (4): 1221-1229.
53. Schwarting A, Schlaak J, Gilbert B, Meyer-zum-Buschenfelde KH, Meyet WJ: Expression of proteinase 3-mRNA in human renal tubular epithelial cells as target cells for antibodies to proteinase 3. Clin Exp Immunol 1995; 101 (S1): 44 (abstract 12).
54. King WJ, Adu D, Savage COS: Endothelial and epithelial expression of proteinase 3, the autoantigen for c-ANCA. Clin Exp Immunol 1995; 101 (S1): 37 (abstract 11).
55. Savage COS: The entothelial cell: active participant or innocent bystander in primary vasculitis? Clin Exp Immunol 1993; 93 (S1): 6-7.
56. van de Wiel BA, Dolman KM, van der Meer-Genitsen CH, Hack CE, van dem Borne AEGKr; Goldschmeding R: Interference of Wegener's granulomatosis autoantibodies with neutrophil proteinase 3 activity. Clin Exp Immunol 1992; 90: 409-414.
57. Dolman KM, Stegeman CA, van de Wiel BA et al.: Relevance of classic anti-neutrophil cytoplasmic autoantibody (c-ANCA)-mediated inhibition of protenase 3-alpha 1-antitrypsin complexation to discase activity in Wegener's granulomatosis. Clin Exp Immunol 1993; 93 (3): 405-410.
58. Esnault VLM, Testa A, Audrain M, Roge C et al: Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int 1993; 43 (6): 1329-1332.
59. Griffith ME, Lovegrove J, Gaskin G, Whitehouse D: P-ANCA positivity in systemic vasculitis is associated with the S allele of α:AT and C-ANCA is associated with the Z allele. Clin Exp Immunol 1995; 101 (S1): 46 (abstract 29).